Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Xencor, Inc.

Biotech SG&A Trends: Soleno vs. Xencor (2014-2023)

__timestampSoleno Therapeutics, Inc.Xencor, Inc.
Wednesday, January 1, 201429175137461000
Thursday, January 1, 2015787829111960000
Friday, January 1, 2016836679413108000
Sunday, January 1, 2017661038117501000
Monday, January 1, 2018655600022472000
Tuesday, January 1, 2019693000024286000
Wednesday, January 1, 2020875800029689000
Friday, January 1, 20211080600038837000
Saturday, January 1, 2022984400047489000
Sunday, January 1, 20231348100053379000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: SG&A Trends from 2014 to 2023

In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Soleno Therapeutics, Inc. and Xencor, Inc. have navigated their financial landscapes with varying strategies. From 2014 to 2023, Xencor's Selling, General, and Administrative (SG&A) expenses surged by over 600%, peaking at approximately $53 million in 2023. This reflects a strategic expansion, possibly linked to increased R&D and market penetration efforts. In contrast, Soleno's SG&A expenses grew by about 360%, reaching around $13 million in 2023. This more conservative growth suggests a focus on streamlined operations and targeted investments. The data highlights the diverse approaches these companies take in balancing growth and cost management, offering valuable insights into their strategic priorities in the ever-evolving biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025